Fig. 6
MCC950 inhibits NLRP3 inflammasome pathway in COPD rat model. Rats were infected with IAV (2.5 × 103 PFU intratracheal) and treated with MCC950 (10 mg/kg intranasal daily) or saline control beginning on day 1 post-infection. BALF were collected on 7 days’ post-infection. A Mortality of Normal rats, B Mortality of COPD rats, C Weight loss was recorded; D IL-1β and E IL-18 in BALF were measured by ELISA. F IL-1β and G IL-18 in serum were measured by ELISA. The mRNA expression level of H NLRP3, I ASC, J Caspase-1, K IL-1β and L IL-18 were measured in lung homogenates by qRT-PCR. M NLRP3 inflammasome pathway protein expression were measured in lung homogenates by western blot N and normalized to β-actin. (*denote P < 0.05, **denotes P < 0.01, ***denotes P < 0.001). Data are presented as the mean ± SD of eight rats per group